Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results
![](https://www.zymeworks.com/wp-content/uploads/2023/04/antibody-stock.jpg)
Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference
![](https://www.zymeworks.com/wp-content/uploads/2023/11/Zymeworks-Lab-21_sized-1024x684.jpg)
We are pleased to present preclinical data associated with our Trispecific T Cell Engager (TriTCE) therapeutic programs in two poster presentations at the annual SITC Conference, taking place November 1-4 in San Diego, CA. The poster presentation titled “TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the […]
Zymeworks Announces Participation in Upcoming Investor Conferences
![](https://www.zymeworks.com/wp-content/uploads/2023/05/asian-male-scientist-at-hood_web-1024x664.jpg)
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
![](https://www.zymeworks.com/wp-content/uploads/2023/01/AdobeStock_407435389-1-1024x683.jpeg)
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the European Society of Medical Oncology (ESMO) Annual Congress taking place October 20-24 in Madrid, Spain. Poster Presentation Information: Title: Zanidatamab (zani) […]
Zymeworks To Host Third Quarter 2023 Results Conference Call
![](https://www.zymeworks.com/wp-content/uploads/2022/12/zymeworks-pipeline-1024x682.jpeg)
Zymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences
![](https://www.zymeworks.com/wp-content/uploads/2023/04/ZYME-Lab-1_news-1024x684.jpg)
Zymeworks is pleased to announce new and updated clinical and preclinical data presentations at the following medical conferences. 14th Annual World Bispecific Summit October 2-4, 2023 Boston, MA Dr. Nina Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks will lead a seminar on Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid […]
Zymeworks To Host Second Quarter 2023 Results Conference Call
![](https://www.zymeworks.com/wp-content/uploads/2023/01/scientist-in-lab-4-1024x576.jpeg)
Zymeworks Announces Participation in Upcoming Investor Conference
![](https://www.zymeworks.com/wp-content/uploads/2023/07/south-asian-female-scientist_web-1024x683.jpg)
Zymeworks Appoints New Director
![](https://www.zymeworks.com/wp-content/uploads/2023/06/pipette-and-microscope-close-up_web-1024x683.jpg)
Zymeworks Set To Join Russell 3000®, Russell 2000®, And Russell Microcap® Indexes
![](https://www.zymeworks.com/wp-content/uploads/2023/02/scientist-in-lab-3-1024x576.jpeg)
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
![](https://www.zymeworks.com/wp-content/uploads/2023/01/211005-ALX-FPI-1024x494.jpg)
Zymeworks Announces Participation In Upcoming Investor Conferences
![](https://www.zymeworks.com/wp-content/uploads/2023/04/antibody-stock.jpg)